BioWorld

April 7, 2003

Administration Won't Reimburse Failed Project BioShield Drugs

Senior Bush administration officials said companies contracted to develop biomedical countermeasures under Project BioShield would not receive full government payment until the FDA approved their products. (BioWorld Today) Read More

For Biotech, Speaker Declares: 'I've Never Seen A Better Time'

Palindromic DNA Sequence Allows p53 Target Genes To Kill Off Cancer Cells & Suppress Tumor Formation

Deltagen Gains At Least $10M In Private Financing Commitment

Correction

Memantine Improves Cognition When Combined With Aricept

Affymetrix Stock Falls Fast As It Projects Lower Product Revenue

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...